TD52 enhances cell apoptosis in triple-negative breast cancer (TNBC) cells in vitro and in vivo. TD52 induces TNBC cell apoptosis via Elk1/CIP2A/p-Akt pathway. High Elk1 expression is associated with worse relapse-free survival in patients with TNBC.